Given that this form of injury is a prominent contributor to long-term graft dysfunction in kidney transplant recipients, and that effective therapeutic strategies targeting this process remain limited, the potential of SGLT2 inhibitors in this context represents an area of significant clinical interest. This evidence concerns the gene SLC5A2 and medical procedure.